What is the implementation rate of guideline-recommended therapies in patients with HFrEF according to heart failure duration?
There is a significant implementation gap in the use of newer guideline-directed medical therapies (ARNI, MRA, SGLT2i) for HFrEF, highlighting an urgent need for strategies to improve prescribing practices.
Most patients received RASI and beta-blockers in the first months following HFrEF diagnosis. Use of ARNI, MRA and SGLT2i was limited, both in the early and later time periods. Our findings suggest that strategies to improve guideline-directed use of HFrEF therapies remain urgently needed.
Shahim et al. (Thu,) studied this question.